false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Best of IGCS 2022 Annual Global Meeting
Plenary 04: Surviving PARPs – Separating between O ...
Plenary 04: Surviving PARPs – Separating between Opinions and Facts
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The panel discussion focused on the use of PARP inhibitors in ovarian cancer treatment. The panelists discussed various clinical trials and their results. They addressed questions such as the importance of bevacizumab when using PARP inhibitors in the HRD-negative population, the use of PARP inhibitors in early-stage BRCA mutated patients, the duration of PARP inhibitor treatment, and the challenges of interpreting overall survival data in PARP inhibitor trials. Overall, the panel emphasized the need for further research and data to guide treatment decisions and to better understand the benefits and limitations of PARP inhibitors in different patient populations.
Keywords
PARP inhibitors
ovarian cancer treatment
panel discussion
clinical trials
bevacizumab
HRD-negative population
early-stage BRCA mutated patients
duration of treatment
overall survival data
research
patient populations
Contact
education@igcs.org
for assistance.
×